Evolent Health Current Valuation

EVH Stock

USD 3.90 -0.01 -0.26%

Evolent Health is priced without meaningful earnings support — a reading that maps directly to negative margins and limited earnings visibility. On asset measures, Evolent Health carries a 1.03x P/B and 0.24x P/S. On a growth-adjusted basis the PEG ratio sits at 1.93.

Above Model Estimate

Today

3.90

The intrinsic value estimate for Evolent Health is based on a 3 months horizon. Negative profit margins (-28.49%) signal ongoing profitability risk influencing market valuation. Extending the time horizon generally improves valuation stability.

0.17

Downside

3.38

Intrinsic Value

9.06

Upside

Current intrinsic value estimate framed by downside and upside probability thresholds.

Target Odds

Above Odds

Evolent Health's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account all liquid assets, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

Market Cap + Debt

-

Cash

Current Evolent Health Current Valuation

1.27 B

For investors studying Evolent Health, Current Valuation gives a clear data point within a larger valuation view. When core analysis points to a higher value than the market sets, it may signal a chance for more research. Growth hopes can justify a higher valuation, but only if future earnings are likely to come through. These findings merit weighing with other tools before making investment choices. A price-to-book ratio of 1.03 helps frame the market's assessment of Evolent Health's asset base.

Competition

Fundamental Drivers Relationships

Current Valuation Peer Comparison

Peer comparison of Evolent Health using Current Valuation provides a quantitative benchmark against similar stocks. Identifying gaps in Evolent Health's Current Valuation relative to peers supports more targeted investment analysis.

Evolent Health is currently under evaluation for current valuation among direct rivals.

Important Fundamentals

	Return On Equity TTM	-0.67
	Return On Asset TTM	-0.0013
	Profit Margin TTM	-0.28
	Operating Margin TTM	-0.0206
	Current Valuation	1.27 B
	Shares Outstanding	114.02 M
	Shares Owned By Insiders	1.61 %
	Shares Owned By Institutions	98.39 %
	Number Of Shares Shorted	16.2 M
	Price To Earnings TTM	-13.88 X
	Price To Book TTM	1.03 X
	Price To Sales TTM	0.24 X
	Revenue TTM	1.88 B
	Gross Profit TTM	399.88 M
	EBITDA TTM	-361.31 M
	Net Income TTM	-579.4 M
	Cash And Equivalents TTM	151.86 M
	Cash Per Share TTM	1.57 X
	Total Debt TTM	989.7 M
	Debt To Equity TTM	0.56 %
	Current Ratio TTM	1.03 X
	Book Value Per Share TTM	3.72 X
	Cash Flow From Operations TTM	38.84 M
	Short Ratio TTM	5.24 X
	Earnings Per Share	-5.39 X
	Price To Earnings To Growth	1.93 X
	Target Price	5.18
	Number Of Employees	4.2 K
	Trailing Beta	0.84
	Market Capitalization TTM	454.93 M
	Total Asset TTM	1.9 B
	Retained Earnings TTM	-1.32 B
	Working Capital TTM	121.11 M
	Current Asset TTM	184.46 M
	Current Liabilities TTM	59.51 M
	Net Asset	1.9 B

Financial Metrics, Fundamentals & Methodology

Evolent Health's operating framework helps explain margin behavior, earnings persistence, and funding capacity. Capital intensity is provided as a reference for reinvestment requirements. In recent filings, Evolent Health reported revenue of 1.88 billion, EPS loss of 5.39, negative operating margin of 2.06% as of the latest reporting period.

Evolent Health data is compiled from periodic company reporting and market reference feeds and standardized for comparability. Statement-level metrics reflect company-reported GAAP or IFRS formats for the relevant filing period.

Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board